Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

⁸⁹Zr-Df-IAB22M2C

Radiopharmaceutical · developed by Nektar Therapeutics

Phase 1 Most advanced trial (none active)
NKTR Developer
1 Registered trials

What is ⁸⁹Zr-Df-IAB22M2C?

⁸⁹Zr-Df-IAB22M2C is a zirconium-89 labeled agent studied in metastatic melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Radiopharmaceutical
Therapy area
Oncology
Developer
Nektar Therapeutics (NKTR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04955262 Phase 1 Metastatic Melanoma Withdrawn NKTR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Melanoma

More from Nektar Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NKTR page.

Follow NKTR, the company behind ⁸⁹Zr-Df-IAB22M2C

See NKTR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NKTR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.